What is ALX Oncology Holdings Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ALX Oncology Holdings's annualized net income for the quarter that ended in Mar. 2025 was $-123.02 Mil. ALX Oncology Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $100.96 Mil. Therefore, ALX Oncology Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -121.85%.
The historical rank and industry rank for ALX Oncology Holdings's Return-on-Tangible-Equity or its related term are showing as below:
ALXO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -433.45 Med: -70.97 Max: -21.05
Current: -98.17
During the past 7 years, ALX Oncology Holdings's highest Return-on-Tangible-Equity was -21.05%. The lowest was -433.45%. And the median was -70.97%.
ALXO's Return-on-Tangible-Equity is ranked worse than 71.31% of 1255
companies
in the Biotechnology industry
Industry Median: -43.28
vs ALXO: -98.17
ALX Oncology Holdings Return-on-Tangible-Equity Historical Data
The historical data trend for ALX Oncology Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ALX Oncology Holdings's Return-on-Tangible-Equity
For the Biotechnology subindustry, ALX Oncology Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ALX Oncology Holdings Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 